If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Non-Executive Directors

1 Jul 2013 09:41

RNS Number : 2542I
Akers Biosciences, Inc.
01 July 2013
 



 

1 July 2013

 

 

Akers Biosciences, Inc.

 

("ABI" or the "Company")

 

Appointment of Non-Executive Directors

 

Akers Biosciences, Inc (AIM: AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, today announces that Gavin Moran and Thomas Knox will be appointed to the board as Non-Executive Directors with effect from 1 July 2013.

 

Mr Moran, aged 43, is an Irish national who has previously worked for Shell International in Shell Chemicals, Marketing, Finance and Shell International Trading. He then held a Trading role as a beneficial shareholder at Trafigura, a leading international commodities trading and logistics company based in Amsterdam and then a Trading role as a beneficial shareholder at Sono International based in London. Mr Moran is indirectly interested through Chubeworkx Guernsey Limited, in which he holds a 31.69 per cent. shareholding, 80 million common shares in the Company, which represents 28.70 per cent of the Company's shares and 24.30 per cent. of the Company's voting rights.

 

Mr Knox, aged 72, is a Philadelphia, Pennsylvania-based businessman who has owned, managed, and ultimately sold multiple profitable companies in the software, banking, and health insurance industries including Disc Systems, Inc., Crusader Bank, Gimco International, Kasser Industries and Fidelity Insurance Group. He also served as Chief Executive Officer for United HealthCare of Pennsylvania and served as Special Deputy Rehabilitator & Chief Executive Officer of Fidelity Mutual Life Insurance Co., Pennsylvania's 5th largest insurer. He currently holds 30 million common shares and 10 million preference shares, which represents 10.76 per cent of the Company's shares and 28.78 per cent. of the Company's voting rights.

 

Raymond F. Akers, Executive Chairman of ABI commented, "It gives me great pleasure to welcome Gavin and Thomas to our Board. They have both invested in the company in the past year and bring with them expertise and experience, which will help move the company forward in the future. My colleagues and I are very much looking forward to our working together."

Further information concerning Mr Moran

Gavin Edwin David Moran's directorships (current and within the previous 5 years) are as follows:

 

Current: None

 

Past: None

 

Further information concerning Mr Knox

 

Thomas James Knox, a Chartered Life Underwriter (CLU) and Chartered Financial Consultant (ChFC), has been involved in Philadelphia politics having held the position of Deputy Mayor for the Office of Management and Productivity. Mr Knox is the Chief Executive Officer of Knox Consulting Group, Knox Family Loan Company and INDECS Corp.

Thomas James Knox's directorships (current and within the previous 5 years) are as follows:

 

Current: Knox Consulting Group

Knox Family Loan Company

INDECS Corp

Historic Philadelphia, Inc.

Newman Wine and Spirit Company

ORB Automotive based in Shenzhen, China

 

Past: None

 

There is no further information required relating to Thomas J. Knox or Gavin E.D. Moran to be disclosed under paragraph (g) of Schedule 2 of the AIM Rules.

 

Enquiries:

Thomas A. Nicolette, President and CEO

Tel. +1 856 848 8698

Antony Legge / James Thomas

Daniel Stewart (Nomad and Broker)

 

 

 

Tel. +44 (0)20 7776 6550

 

 

About Akers Biosciences, Inc.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com

 

End

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAVFLBBXDFXBBK
Date   Source Headline
8th May 20181:00 pmRNSHolding(s) in Company
27th Apr 20182:05 pmRNSSecond Price Monitoring Extn
27th Apr 20182:00 pmRNSPrice Monitoring Extension
26th Apr 20187:00 amRNSDirectorate Change
13th Apr 20185:45 pmRNSIssue of Equity
12th Apr 201812:00 pmRNSIndependent Sales Representative Agreements - PIFA
6th Apr 20184:30 pmRNSIssue of Equity
3rd Apr 201811:05 amRNSFinal Results
28th Mar 20184:20 pmRNSNotice of Fiscal Year 2017 Earnings - Rescheduled
26th Mar 20187:01 amRNSDistribution Agreement with Diagnostica Stago
26th Mar 20187:00 amRNSIssue of Equity
16th Mar 20184:00 pmRNSIssue of Equity
15th Mar 20185:30 pmRNSNotice of Results
9th Mar 20186:29 pmRNSIssue of Equity
2nd Mar 20185:15 pmRNSIssue of Equity
16th Feb 20185:45 pmRNSIssue of Equity
14th Feb 20185:30 pmRNSHoldings in Company
9th Feb 20186:00 pmRNSIssue of Equity
2nd Feb 20184:42 pmRNSIssue of Equity
26th Jan 20187:00 amRNSIssue of Equity
22nd Jan 20184:27 pmRNSHoldings in Company
19th Jan 20183:35 pmRNSIssue of Equity
16th Jan 20186:20 pmRNSIssue of Equity
15th Jan 20187:00 amRNSUpdate RE Admission of Shares
12th Jan 20187:00 amRNSIssue of Equity
5th Jan 20186:29 pmRNSIssue of Equity
4th Jan 20184:45 pmRNSHoldings in Company
27th Dec 20172:01 pmRNSIssue of Equity
22nd Dec 20177:00 amRNSClosing of Public Offering
19th Dec 20177:00 amRNSIssue of Equity
18th Dec 201711:00 amRNSForm S-1 Registration Statement - Amendment
15th Dec 201711:00 amRNSForm S-1 Registration Statement - Amendment
14th Dec 201711:00 amRNSForm S-1 Registration Statement - Amendment
11th Dec 201711:00 amRNSForm S-1 Registration Statement - Amendment
8th Dec 20173:30 pmRNSFurther IP Protection for Akers Wellness Line
1st Dec 20172:00 pmRNSForm 8K Filing
27th Nov 20177:00 amRNSForm S-1 Registration Statement
15th Nov 20177:00 amRNS3rd Quarter Results
14th Nov 20177:00 amRNSNew UK Channel for Rapid Alcohol Breathalyzer
13th Nov 20172:00 pmRNSNotice of Results
8th Nov 20171:59 pmRNSIssue of Equity
20th Oct 20177:00 amRNSPDMR Shareholding and Issue of Equity
19th Oct 20174:20 pmRNSDirector/PDMR Shareholding
13th Oct 20172:35 pmRNSWarrant Amendment and Exercise
7th Sep 20177:00 amRNSAppointment of U.S. VP of Sales & Distribution
15th Aug 20177:00 amRNSHalf-year Report
11th Aug 20177:00 amRNSIssue of Equity
8th Aug 20177:00 amRNSResult of AGM
3rd Aug 20174:30 pmRNSTrading Update and Notice of Q2 Results
20th Jul 201711:10 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.